Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
38%
Ph phase_2
3
38%
Ph phase_3
2
25%

Phase Distribution

3

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 32 (25.0%)

Trials by Status

completed675%
withdrawn113%
active_not_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

NCT06040346
completedphase_3

To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19

NCT05813587
completedphase_3

Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

NCT05679479
withdrawnphase_1

Clinical Study of Meplazumab to Treat With Malaria

NCT04327310
completedphase_2

the Safety and Efficacy of Meplazumab in Patients With COVID-19

NCT05113784
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06040346Phase 2

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Active Not Recruiting
NCT05813587Phase 3

To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19

Completed
NCT05679479Phase 3

Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

Completed
NCT04327310Phase 1

Clinical Study of Meplazumab to Treat With Malaria

Withdrawn
NCT05113784Phase 2

the Safety and Efficacy of Meplazumab in Patients With COVID-19

Completed
NCT04586153Phase 2

Study to Assess the Effect of Meplazumab on COVID-19

Completed
NCT04369586Phase 1

A Phase I Clinical Trial of Meplazumab in Healthy Volunteer

Completed
NCT04275245Phase 1

Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8